Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
Despite the introduction of novel therapies that maximally decrease androgen-receptor (AR) signaling activity, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease. Even though abiraterone and enzalutamide represent breakthroughs in the treatment of mCRPC and have demonst...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Libertas Academica
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798019/ |